Kenneth Offit

Memorial Sloan Kettering Cancer Center

Full Professor(heuristic)

BRCA gene mutations in cancer · Genetics

h-index114

i10-index354

Publications836

Citations44,833

Grants

18 total · 1 active

NIH #5R01HG011914-04

Digital Technology to Enhance Access to and Effectiveness of Cancer Genetic Counseling

Active

Amount: $844K
Period: 2022-08-15 → 2027-05-31
PIs: 2
Est. capacity / PI: ~1 students

Awarded at SLOAN-KETTERING INST CAN RESEARCH

NIH #5R01HG011914-03

Digital Technology to Enhance Access to and Effectiveness of Cancer Genetic Counseling

Amount: $850K
Period: 2022-08-15 → 2026-05-31
PIs: 2
Est. capacity / PI: ~0 students

Awarded at SLOAN-KETTERING INST CAN RESEARCH

NIH #5R01HG011914-02

Digital Technology to Enhance Access to and Effectiveness of Cancer Genetic Counseling

Amount: $877K
Period: 2022-08-15 → 2026-05-31
PIs: 2
Est. capacity / PI: ~0 students

Awarded at SLOAN-KETTERING INST CAN RESEARCH

Student capacity is a rough estimate from remaining award size, split equally among PIs. Actual funding decisions vary.

All Grants

18 total · 1 active

NIH #5R01HG011914-04

Digital Technology to Enhance Access to and Effectiveness of Cancer Genetic Counseling

Active

Amount: $844K
Period: 2022-08-15 → 2027-05-31
PIs: 2
Est. capacity / PI: ~1 students

Awarded at SLOAN-KETTERING INST CAN RESEARCH

NIH #5R01HG011914-03

Digital Technology to Enhance Access to and Effectiveness of Cancer Genetic Counseling

Amount: $850K
Period: 2022-08-15 → 2026-05-31
PIs: 2
Est. capacity / PI: ~0 students

Awarded at SLOAN-KETTERING INST CAN RESEARCH

NIH #5R01HG011914-02

Digital Technology to Enhance Access to and Effectiveness of Cancer Genetic Counseling

Amount: $877K
Period: 2022-08-15 → 2026-05-31
PIs: 2
Est. capacity / PI: ~0 students

Awarded at SLOAN-KETTERING INST CAN RESEARCH

NIH #1R01HG011914-01A1

Digital Technology to Enhance Access to and Effectiveness of Cancer Genetic Counseling

Amount: $885K
Period: 2022-08-15 → 2026-05-31
PIs: 2
Est. capacity / PI: ~0 students

Awarded at SLOAN-KETTERING INST CAN RESEARCH

NIH #5P01CA228696-05

The Clinical and Epidemiological Characterization of Pathogenic DNA Damage Repair Pathway Variation in Prostate Cancer

Amount: $284K
Period: 2019-09-01 → 2026-02-28
PIs: 1
Est. capacity / PI: ~0 students

Awarded at SLOAN-KETTERING INST CAN RESEARCH

NIH #5P01CA228696-04

The Impact of DNA Damage Repair Abnormalities in Prostate Cancer

Amount: $1.7M
Period: 2019-09-01 → 2025-08-31
PIs: 2
Est. capacity / PI: ~0 students

Awarded at SLOAN-KETTERING INST CAN RESEARCH

NIH #5P01CA228696-03

The Impact of DNA Damage Repair Abnormalities in Prostate Cancer

Amount: $1.7M
Period: 2019-09-01 → 2025-08-31
PIs: 2
Est. capacity / PI: ~0 students

Awarded at SLOAN-KETTERING INST CAN RESEARCH

NIH #5P01CA228696-02

The Impact of DNA Damage Repair Abnormalities in Prostate Cancer

Amount: $1.8M
Period: 2019-09-01 → 2025-08-31
PIs: 2
Est. capacity / PI: ~0 students

Awarded at SLOAN-KETTERING INST CAN RESEARCH

NIH #1P01CA228696-01A1

The Clinical and Epidemiological Characterization of Pathogenic DNA Damage Repair Pathway Variation in Prostate Cancer

Amount: $432K
Period: 2019-09-01 → 2025-08-31
PIs: 1
Est. capacity / PI: ~0 students

Awarded at SLOAN-KETTERING INST CAN RESEARCH

NIH #5R01CA176785-04

Identifying and validating novel susceptibility genes for breast cancer

Amount: $681K
Period: 2014-04-10 → 2019-02-28
PIs: 3
Est. capacity / PI: ~0 students

Awarded at MAYO CLINIC ROCHESTER

NIH #5R01CA176785-03

Identifying and validating novel susceptibility genes for breast cancer

Amount: $675K
Period: 2014-04-10 → 2019-02-28
PIs: 3
Est. capacity / PI: ~0 students

Awarded at MAYO CLINIC ROCHESTER

NIH #5R01CA176785-02

Identifying and validating novel susceptibility genes for breast cancer

Amount: $677K
Period: 2014-04-10 → 2019-02-28
PIs: 3
Est. capacity / PI: ~0 students

Awarded at MAYO CLINIC ROCHESTER

NIH #1R01CA176785-01A1

Identifying and validating novel susceptibility genes for breast cancer

Amount: $705K
Period: 2014-04-10 → 2019-02-28
PIs: 3
Est. capacity / PI: ~0 students

Awarded at MAYO CLINIC ROCHESTER

NIH #4R01CA167824-05

Whole Genome Sequencing to Discover Familial Myeloma Risk Genes

Amount: $494K
Period: 2012-09-27 → 2018-06-30
PIs: 2
Est. capacity / PI: ~0 students

Awarded at WEILL MEDICAL COLL OF CORNELL UNIV

NIH #5R01CA167824-03

Whole Genome Sequencing to Discover Familial Myeloma Risk Genes

Amount: $331K
Period: 2012-09-27 → 2017-06-30
PIs: 2
Est. capacity / PI: ~0 students

Awarded at WEILL MEDICAL COLL OF CORNELL UNIV

NIH #5R01CA167824-02

Whole Genome Sequencing to Discover Familial Myeloma Risk Genes

Amount: $320K
Period: 2012-09-27 → 2017-06-30
PIs: 2
Est. capacity / PI: ~0 students

Awarded at WEILL MEDICAL COLL OF CORNELL UNIV

NIH #1R01CA167824-01A1

Whole Genome Sequencing to Discover Familial Myeloma Risk Genes

Amount: $392K
Period: 2012-09-27 → 2017-06-30
PIs: 2
Est. capacity / PI: ~0 students

Awarded at WEILL MEDICAL COLL OF CORNELL UNIV

NIH #5R01CA167824-04

Whole Genome Sequencing to Discover Familial Myeloma Risk Genes

Amount: $351K
Period: 2012-09-27 → 2016-06-30
PIs: 2
Est. capacity / PI: ~0 students

Awarded at WEILL MEDICAL COLL OF CORNELL UNIV

Lab Funding Health

Find elsewhere

Institution / lab homepage Search on ResearchGate

In-Field Influence

0.0048

PageRank within Genetics co-authorship network

Explore collaboration map

Admission Signals

New paper: Supplementary Data from Case-Case Genome-Wide Analyses Identify Subtype-Informative Variants That Confer Risk for Breast Cancer2026-06-17
New NIH award: $844K — Digital Technology to Enhance Access to and Effectiveness of Cancer Genetic Counseling2022-08-15

Data Freshness

Publications as of 2026-07-01
Grants as of 2026-06-30

Are you this professor?

No account needed — verify once with your ORCID iD to set recruiting status and correct your rank.

ORCID: 0000-0002-2180-2032

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 50

Supplementary Data from Case-Case Genome-Wide Analyses Identify Subtype-Informative Variants That Confer Risk for Breast Cancer
2026-06-17
Prevalence, tumor characteristics, and clinical impact of LZTR1 pathogenic variants in a large, pan-cancer cohort.
Journal of Clinical Oncology · 2026-05-27
Data from Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations
2025-12-17
Supplemental Table 1, Supplemental Table 2, Supplemental Table 3, Supplemental Table 6, Supplemental Table 7, Supplemental Figure 1, and Supplemental Figure 2 from Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations
2025-12-17
Supplemental Table 4 from Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations
2025-12-17
Supplemental Materials and Methods from Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations
2025-12-17
Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer
2025-11-26
Supplementary Data from SNPs at SMG7 Associated with Time from Biochemical Recurrence to Prostate Cancer Death
2025-11-26
Data from Genetic Predictors for Fecal Propionate and Butyrate-Producing Microbiome Pathway Are Not Associated with Colorectal Cancer Risk: A Mendelian Randomization Analysis
2025-11-26
Supplementary Figure from SNPs at SMG7 Associated with Time from Biochemical Recurrence to Prostate Cancer Death
2025-11-26
Supplementary Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer
2025-11-26
Data from SNPs at SMG7 Associated with Time from Biochemical Recurrence to Prostate Cancer Death
2025-11-26
Supplementary Table 1 from Genetic Predictors for Fecal Propionate and Butyrate-Producing Microbiome Pathway Are Not Associated with Colorectal Cancer Risk: A Mendelian Randomization Analysis
2025-11-26
Supplementary Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer
2025-11-26
Figure S2 from NBN Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and In Vitro DNA Damage Response Defects
2025-11-25
Figure S1 from NBN Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and In Vitro DNA Damage Response Defects
2025-11-25
Figure S5 from NBN Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and In Vitro DNA Damage Response Defects
2025-11-25
Figure S4 from NBN Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and In Vitro DNA Damage Response Defects
2025-11-25
Figure S3 from NBN Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and In Vitro DNA Damage Response Defects
2025-11-25
Supplementary Tables S1-S11 from NBN Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and In Vitro DNA Damage Response Defects
2025-11-25

Open author page on OpenAlex →